PanTher Therapeutics

Leadership

Meg Lashof-Sullivan, PhD

Meg Lashof-Sullivan, PhD is Director of R&D at PanTher Therapeutics. As a biomedical engineer with a background in biomaterials, Meg has expertise in polymer synthesis, drug delivery, and analytical laboratory techniques. She has led the transfer of PanTher’s PTM-101 from the academic laboratory to a clinical manufacturing process. She developed the in-house testing methods used to characterize the PTM-101 prototype and has overseen the external pre-clinical studies necessary to bring PTM-101 to the clinic.

Prior to joining PanTher Therapeutics, Meg completed her postdoctoral fellowship at The Henry M. Jackson Foundation for the Advancement of Military Medicine at the Naval Medical Research Center’s NeuroTrauma department. Before that,she served as a General Engineer at the U.S. Department of Energy.

Meg holds a PhD in Biomedical Engineering from Case Western Reserve University and both a BE in Engineering and BA in Biology and Engineering from Dartmouth College.

David Mackey

David Mackey is a senior finance and operations executive with a 20-year track record of success building, leading, and advising businesses in all phases of the corporate life cycle.  In addition to serving as the Chief Financial Officer of Catalyst Health Ventures (CVH), he has been a strategic, financial, and operational advisor to PanTher Therapeutics since 2020.

Prior to joining the PanTher Therapeutics, David served as President and Chief Financial Officer of Lantos Technologies, where he led numerous strategic financings and was responsible for business and manufacturing operations, and Chief Financial Officer and Vice President, Business Development of AgNovos Healthcare, where he designed and built out the financial and operational infrastructure.  Before that, he served as Vice President, Investment Banking at J.P. Morgan.

David began his career as a corporate attorney at Gibson, Dunn & Crutcher. He holds a JD from the University of Pennsylvania Law School and a BA in Journalism from Colorado State University.

Laura Indolfi, PhD

Laura Indolfi, PhD is the Chief Executive Officer and Co-Founder of PanTher Therapeutics. Laura combines science and business knowledge to drive PanTher’s vision. Prior to founding PanTher Therapeutics, she was a postdoctoral associate at the Harvard-MIT Institute for Medical Engineering and Science and served as an entrepreneur-in-residence at the Massachusetts General Hospital Cancer Center.

Laura’s broad professional experience and interests range from biomedical engineering to entrepreneurship and outreach initiatives to promoting science. Her scientific expertise covers multiple therapeutic areas (cardio, cancer, inflammation, regenerative medicine) and approaches (drug delivery, cell therapy, implanted devices). Together with her strong technical background, Laura has hands-on business and managerial know-how developed during her biomedical business training at Sloan and Harvard Business Schools and with several consulting firms.

She was named a TED Fellow, one of 21 people chosen annually by the TED organization who are considered the most disruptive and transformative change-makers in the world. Laura has also attended the prestigious conference “Fortune: Most Powerful Women – Next Gen”, an invite-only summit hosted by Fortune gathering a stellar group of game-changing entrepreneurs, executives, and innovators in business. Laura is also one of the five women selected by Massachusetts Life Science Center and Takeda for their inaugural class in 2018 of the MassNextGen program, honoring exceptional leaders in the biotech industry.

Laura holds a PhD in Biomaterials and MS and BS degrees in Materials Science and Engineering from the University of Naples Federico II in Italy.